David Shau, MD
Orthopaedic Surgery · Fort Worth, TXNPI 1366839326
Payments from drug & device makers
Across 261 payments — averaging $273.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$22K
- UOC USA Inc$21K
- Acera Surgical, Inc.$9K
- Stryker$7K
- Depuy Synthes Products, Inc.$6K
- Heraeus Medical, LLC.$2K
- plus $5K from 28 others
What the payments were for
- Consulting fees$30,25742%
- Speaking & faculty fees$6,6729%
- Travel & lodging$22,09431%
- Food & beverage$12,43417%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 23 | $21,514 |
| UOC USA Inc | 43 | $20,564 |
| Acera Surgical, Inc. | 13 | $8,808 |
| Stryker | 68 | $7,343 |
| Depuy Synthes Products, Inc. | 13 | $5,765 |
| Heraeus Medical, LLC. | 21 | $2,492 |
| Johnson & Johnson(2 entities) | 18 | $925 |
| Shalby Advanced Technologies, Inc. | 6 | $696 |
| Kyocera Medical Technologies, Inc. | 1 | $319 |
| Davol Inc. | 9 | $289 |
| Vertex | 9 | $263 |
| Smith+Nephew | 4 | $223 |
| Oxford Performance Materials, Inc. | 1 | $219 |
| Pylant Medical | 2 | $207 |
| Corentec America Inc | 1 | $193 |
| Intellijoint Surgical Inc. | 1 | $174 |
| Pacira Pharmaceuticals Incorporated | 3 | $170 |
| Zimmer Biomet | 1 | $152 |
| Medacta USA, Inc. | 1 | $146 |
| Nalu Medical, Inc. | 1 | $142 |
| Convatec Inc. | 2 | $136 |
| Next Science LLC | 1 | $132 |
| Innovation Technologies Inc | 4 | $103 |
| Ferring Pharmaceuticals Inc. | 4 | $89 |
| Maxx Orthopedics, Inc. | 1 | $87 |
| Orthalign Inc | 1 | $71 |
| Biocomposites Inc | 1 | $49 |
| Kinamed, Inc. | 1 | $41 |
| Medtronic | 2 | $36 |
| Bioventus LLC | 1 | $26 |
| Nevro Corp. | 1 | $26 |
| Si-bone, Inc. | 1 | $24 |
| Heron Therapeutics, Inc. | 1 | $18 |
| Curonix LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- U2, Conformity, U-Motion II and USTAR II$11,777
- Restrata Wound Matrix$8,778
- MAKO$5,149
- PSA, U-Star II$3,060
- U2$2,095
- PALACOS$1,376
- Velys$1,374
- U2, PSA, U-Star II$1,275
- USTAR II$951
- CONSENSUS KNEE SYSTEM$637
- CKS- Vitalite$637
- Kincise$583
- Corentec$193
- U-Star, Conformity, U2$188
- CONSENSUS HIP SYSTEM$178
- Taperset Reduced Distal Profile$178
- Acetabular Shell$178
- CS2 Acet. Cup Sys. - VitalitE$178
- Intellijoint$174
- STRYKER NAV3I$160
How this compares
$71,456 in reported general payments places this provider in the 90th percentile of 1,337 orthopaedic surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 26 | $18,840 |
| Oxycodone Hcl | 257 | $2,534 |
| Lansoprazole | 42 | $2,517 |
| Ondansetron OdtOndansetron | 223 | $2,019 |
| Celecoxib | 120 | $1,615 |
| Tizanidine Hcl | 276 | $1,429 |
| Doxycycline Hyclate | 139 | $988 |
| Gabapentin | 210 | $502 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 24 | $330 |
| Meloxicam | 64 | $154 |
| Tramadol Hcl | 17 | $105 |
| Cephalexin | 13 | $66 |
| Amoxicillin | 39 | $49 |
| Clindamycin Hcl | 11 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $925 | $18,84026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,337 orthopaedic surgery providers in Texas.
Other orthopaedic surgery in Fort Worth
- Robert SchmidtFort Worth$2M
- Stephen BurkhartSan Antonio$185.3M
- Kirby HittTemple$9.1M
- J Richard EvansonPlano$8.1M
- Stefan KreuzerHouston$7M
- Robert GrahamAustin$6.3M
- Richard JonesDallas$6.3M
- Howard HarrisBedford$4.6M
- Tiffany HuynhHouston$4.6M
- Michael WirthSan Antonio$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.